Outlook Therapeutics Inc (OTLK)
7.33
-0.10
(-1.35%)
USD |
NASDAQ |
May 16, 16:00
7.49
+0.16
(+2.18%)
Pre-Market: 20:00
Outlook Therapeutics Research and Development Expense (Annual): 26.45M for Sept. 30, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| September 30, 2023 | 26.45M |
| September 30, 2022 | 42.33M |
| September 30, 2021 | 38.96M |
| September 30, 2020 | 26.34M |
| September 30, 2019 | 23.81M |
| Date | Value |
|---|---|
| September 30, 2018 | 18.50M |
| September 30, 2017 | 23.81M |
| September 30, 2016 | 32.76M |
| September 30, 2015 | 38.88M |
| September 30, 2014 | 14.12M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
23.81M
Minimum
2019
42.33M
Maximum
2022
31.58M
Average
26.45M
Median
2023
Research and Development Expense (Annual) Benchmarks
| Cutera Inc | 21.41M |
| Actinium Pharmaceuticals Inc | 38.67M |
| GT Biopharma Inc | 6.466M |
| Karyopharm Therapeutics Inc | 138.75M |
| Marinus Pharmaceuticals Inc | 99.39M |